Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock - Investor's Business Daily

Novo Nordisk's second-quarter results disappointed despite a guidance boost.

Danish drugmaker Novo Nordisk (NVO) missed second-quarter expectations Wednesday but raised its full-year outlook. NVO stock tumbled. XSales climbed 25% to 41.27 million Danish Kroner or about $5.62… [+1982 chars]

full article...